Press Releases

- Leerink Partners 8 th Annual Global Healthcare Conference on February 28, 2019 - - Cowen and Company 39 th Annual Health Care Conference on March 11, 2019 - LONDON and CARLSBAD, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the

LONDON, Feb. 07, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 26 February, 2019 its

LONDON and CARLSBAD, Calif., Dec. 31, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that

- Epidiolex ® (cannabidiol) oral solution (CV), first FDA -approved plant-derived cannabinoid medicine launched in the U.S. - - Conference call today at 4:30 p.m. EST - LONDON and CARLSBAD, Calif. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the

- Primary endpoint achieved with both EPIDIOLEX doses compared to placebo -  - Today’s data represents the fourth positive Phase 3 pivotal trial for EPIDIOLEX in Dravet syndrome and Lennox-Gastaut Syndrome - - EPIDIOLEX recently launched in the US and is now available by prescription -   LONDON,

Meeting Highlights Include over 20 Posters and Virtual Tour of the Epidiolex Manufacturing Process LONDON and CARLSBAD, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and commercialization of

LONDON , Nov. 06, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 27 November, 2018 its

- Medication indicated for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, two rare, severe childhood-onset epilepsies - - Comprehensive support program available for eligible patients - LONDON and CARLSBAD, Calif., Nov.

LONDON and CARLSBAD, Calif. , Oct. 05, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today

LONDON and CARLSBAD, Calif. , Oct. 02, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today